Related Experiment Videos
Acceleration of reverse cholesterol transport.
A von Eckardstein1, J R Nofer, G Assmann
1Institut für Klinische Chemie und Laboratoriumsmedizin, Zentrallaboratorium, Westfälische Wilhelms-Universität Münster, Germany. vonecka@uni-muenster.de
Current Opinion in Cardiology
|December 29, 2000
Summary
Low high-density lipoprotein (HDL) cholesterol increases coronary heart disease risk. Enhancing cholesterol removal from arteries is a therapeutic target, but HDL levels may not always indicate treatment effectiveness.
Area of Science:
- Cardiovascular Science
- Lipid Metabolism
- Atherosclerosis Research
Background:
- Low high-density lipoprotein (HDL) cholesterol is a significant risk factor for coronary heart disease (CHD).
- HDL cholesterol levels and subclass composition are influenced by numerous biological factors.
- Reverse cholesterol transport (RCT) via HDL is crucial for preventing atherosclerosis.
Purpose of the Study:
- To investigate the relationship between HDL cholesterol levels and the efficacy of reverse cholesterol transport.
- To evaluate RCT as a therapeutic target for anti-atherosclerotic drug development.
Main Methods:
- Analysis of factors regulating HDL cholesterol and its subclasses.
- Assessment of reverse cholesterol transport mechanisms from arterial wall cells to the liver.
Main Results:
- Serum HDL cholesterol levels may not accurately reflect the efficiency of reverse cholesterol transport.
- HDL's anti-atherogenic properties are linked to its role in RCT.
Conclusions:
- Targeting RCT enhancement holds potential for anti-atherosclerotic therapies.
- Relying solely on serum HDL cholesterol levels may be insufficient to gauge therapeutic success in RCT enhancement.